Hereditäre hämorrhagische Teleangiektasie: Symptome und diagnostische Latenz

Zusammenfassung

Hintergrund Patienten mit hereditärer hämorrhagischer Teleangiektasie (HHT) leiden unter einer systemischen Erkrankung des Gefäßbindegewebes, bei der eine Vielzahl verschiedener Symptome auftritt.

Material und Methoden Die Daten aller Patienten, die sich von April 2014 bis August 2019 im Westdeutschen Morbus-Osler-Zentrum vorstellten, wurden in einer retrospektiven Studie analysiert.

Ergebnisse Bei 235 Patienten konnte die Diagnose HHT als definitiv (235/282; 83 %) und bei 26 als möglich gestellt werden (26/282; 9 %). Die mittlere diagnostische Latenz zwischen Erstsymptomen und Diagnose betrug 18 Jahre. Direkte oder indirekte Blutungszeichen wurden oft als erste Symptome der Erkrankung HHT genannt (224/241; 93 %). 83 % der Patienten mit einem Grad der Behinderung gaben HHT als Hauptursache an. Insbesondere ältere, weibliche Patienten bzw. Patienten mit starker Epistaxis litten an einer chronischen Eisenmangelanämie (Eisensubstitution:148/261; 57 %; Erythrozytenkonzentrate: Mittelwert: 9 ± Standardabweichung: 41, Minimum – Maximum: 0–400, Anzahl der Patienten: 218). 10 % erhielten eine Thrombozytenaggregationshemmung oder Antikoagulation und tolerierten diese. 74 % der Patienten mit HHT pflegten ihre Nasenschleimhaut (177/238) und zeigten weniger Blutungen als Patienten ohne Nasenpflege (ESS: t-Test: 3,193; p = 0,003; Anämie: Chi-Quadrat: 5,173; p = 0,023).

Schlussfolgerungen Die Diagnoselatenz der Erkrankung HHT betrug knapp 2 Jahrzehnte. Patienten mit HHT leiden insbesondere an rezidivierenden Blutungen, die dabei meistindizierte Behandlung der ersten Wahl ist eine konsequente Nasenpflege und verschiedene koagulative Therapieoptionen. Bei Begleiterkrankungen mit Indikation zur Gerinnungshemmung lohnt es sich meist, deren Einsatz zu versuchen.

Abstract

Objective Patients with hereditary hemorrhagic Telangiectasia (HHT) suffer from a rare and systemic disease which is characterized by vascular malformations leading to a variety of different symptoms.

Material and Methods A retrospective review of patients who were referred to our new HHT Center of Excellence (HHT COE) for evaluation and treatment between April 2014 and August 2019 was performed.

Results 235 patients were treated at the West German HHT Center. 83 % of these were diagnosed with definite HHT (235/282, 83 %) and 9 % with possible HHT (26/282). The average latency between first manifestation and definite diagnosis of HHT was 18 years. Several initial symptoms were direct or indirect signs of bleeding (224/241, 93 %). In 83 % of the patients HHT was reported having caused their degree of disability. Older, female patients and those with severe epistaxis suffered from chronic iron deficiency anemia, took iron preparations (148/261, 57 %) and received 9 blood transfusions on average (± standard deviation: 41, minimum – maximum: 0–400, number of patients: 218). 10 % of all patients tolerated anticoagulant or antiplatelet agents. 74 % of patients with HHT used nasal creams/sprays/oils (177/238) and reported fewer bleedings compared to patients without nasal care (ESS: T-Test: 3.193; p = 0.003; anemia: Chi-square: 5.173; p = 0.023).

Conclusions The diagnostic latency of HHT was almost two decades. Patients with HHT particularly suffered from recurrent epistaxis, which was mostly treated with nasal care and coagulative therapies. Antiplatelet or anticoagulant agents can be used in patients with HHT with caution if indicated.

Schlüsselwörter

hereditäre hämorrhagische Teleangiektasie (HHT) - Epistaxis - seltene Erkrankungen - Anämie - Diagnoselatenz

Key words

hereditary hemorrhagic telangiectasia (HHT) - epistaxis - rare diseases - anemia - diagnostic latency

Publication History

Received: 11 April 2020

Accepted: 02 March 2021

Article published online:
24 March 2021

• Literatur

• 1 Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. Journal of Internal Medicine 1999; 245: 31-39
• 2 McDonald J, Wooderchak-Donahue W, VanSant Webb C. et al Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era. Front Genet 2015; 6: 1
• 3 Dakeishi M, Shioya T, Wada Y. et al Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat 2002; 19: 140-148
• 4 Osler W. On a Family Form of Recurring Epistaxis Associated with Multiple Telangiectases of the Skin and Mucous Membranes. Johns Hopkins Hosp. Bull., 12, 333-337, 1901.(b) Dickson, WEC: Certain Intracranial Tumors; Their Variability and Multiplicity. Brit Med Jour 1901; 2: 333-337
• 5 Shovlin CL, Guttmacher AE, Buscarini E. et al Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). American journal of medical genetics 2000; 91: 66-67
• 6 Plauchu H, de Chadarevian JP, Bideau A. et al Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. American journal of medical genetics 1989; 32: 291-297
• 7 Seebauer CT, Kuehnel T, Uller W. et al [Diagnostic Criteria and Treatment of Hereditary Hemorrhagic Telangiectasia]. Laryngorhinootologie 2020; 99: 682-693
• 8 Droege F, Thangavelu K, Stuck BA. et al Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia. Vasc Med 2018;
• 9 Stell PM. Epistaxis. Clin Otolaryngol Allied Sci 1977; 2: 263-273
• 10 Shovlin CL, Jackson JE, Bamford KB. et al Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax 2008; 63: 259-266
• 11 Circo S, Gossage JR. Pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Curr Opin Pulm Med 2014; 20: 421-428
• 12 Faughnan ME, Granton JT, Young LH. The pulmonary vascular complications of hereditary haemorrhagic telangiectasia. Eur Respir J 2009; 33: 1186-1194
• 13 Hoag JB, Terry P, Mitchell S. et al An epistaxis severity score for hereditary hemorrhagic telangiectasia. The Laryngoscope 2010; 120: 838-843
• 14 WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization; 2011
• 15 Hahn JM. Laborwerte – Normalbereiche. In Checkliste Innere Medizin: Georg Thieme Verlag; 2006: 777-780
• 16 van Gent MWF, Post MC, Snijder RJ. et al Grading of pulmonary right-to-left shunt with transthoracic contrast echocardiography: does it predict the indication for embolotherapy?. Chest 2009; 135: 1288-1292
• 17 Li S, Wang SJ, Zhao YQ. Clinical features and treatment of hereditary hemorrhagic telangiectasia. Medicine (Baltimore) 2018; 97: e11687
• 18 Pierucci P, Lenato GM, Suppressa P. et al A long diagnostic delay in patients with Hereditary Haemorrhagic Telangiectasia: a questionnaire-based retrospective study. Orphanet J Rare Dis 2012; 7: 33
• 19 OS AA, Friedman CM, White Jr RI. The natural history of epistaxis in hereditary hemorrhagic telangiectasia. The Laryngoscope 1991; 101: 977-980
• 20 Kjeldsen A, Aagaard KS, Torring PM. et al 20-year follow-up study of Danish HHT patients-survival and causes of death. Orphanet J Rare Dis 2016; 11: 157
• 21 Solomon RA, Connolly Jr ES. Arteriovenous Malformations of the Brain. N Engl J Med 2017; 376: 1859-1866
• 22 van Gent MW, Post MC, Snijder RJ. et al Real prevalence of pulmonary right-to-left shunt according to genotype in patients with hereditary hemorrhagic telangiectasia: a transthoracic contrast echocardiography study. Chest 2010; 138: 833-839
• 23 Cirulli A, Loria MP, Dambra P. et al Patients with Hereditary Hemorrhagic Telangectasia (HHT) exhibit a deficit of polymorphonuclear cell and monocyte oxidative burst and phagocytosis: a possible correlation with altered adaptive immune responsiveness in HHT. Curr Pharm Des 2006; 12: 1209-1215
• 24 Amati L, Passeri ME, Resta F. et al Ablation of T-helper 1 cell derived cytokines and of monocyte-derived tumor necrosis factor-alpha in hereditary hemorrhagic telangiectasia: immunological consequences and clinical considerations. Curr Pharm Des 2006; 12: 1201-1208
• 25 Guilhem A, Malcus C, Clarivet B. et al Immunological abnormalities associated with hereditary haemorrhagic telangiectasia. J Intern Med 2013; 274: 351-362
• 26 Droege F, Pylaeva E, Siakaeva E. et al Impaired Release of Neutrophil Extracellular Traps and Anemia-Associated T Cell Deficiency in Hereditary Hemorrhagic Telangiectasia. J Clin Med 2020; 9
• 27 Shovlin CL, Buscarini E, Kjeldsen AD. et al European Reference Network For Rare Vascular Diseases (VASCERN) Outcome Measures For Hereditary Haemorrhagic Telangiectasia (HHT). Orphanet J Rare Dis 2018; 13: 136
• 28 Arbeit Bf. Fachliche Weisungen SB Neuntes Buch Sozialgesetzbuch – SGB IX, §2 SGB IX Begriffbestimmungen. 2017
• 29 Geisthoff UW, Heckmann K, D'Amelio R. et al Health-related quality of life in hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 2007; 136: 726-733 ; discussion 734-725.
• 30 Park SO, Wankhede M, Lee YJ. et al Real-time imaging of de novo arteriovenous malformation in a mouse model of hereditary hemorrhagic telangiectasia. The Journal of clinical investigation 2009; 119: 3487-3496
• 31 Faughnan ME, Mager JJ, Hetts SW. et al Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med 2020;
• 32 Faughnan ME, Palda VA, Garcia-Tsao G. et al International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. Journal of medical genetics 2011; 48: 73-87
• 33 Wirsching KEC, Haubner F, Kuhnel TS. Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT). European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery 2017; 274: 1891-1896
• 34 Mei-Zahav M, Blau H, Bruckheimer E. et al Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia – a preliminary report. J Otolaryngol Head Neck Surg 2017; 46: 58
• 35 Karnezis TT, Davidson TM. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis. The Laryngoscope 2011; 121: 636-638
• 36 Dupuis-Girod S, Ambrun A, Decullier E. et al Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial. JAMA 2016; 316: 934-942
• 37 Dupuis-Girod S, Pitiot V, Bergerot C. et al Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial. Sci Rep 2019; 9: 11986
• 38 Al Kadah B, Papaspyrou G, Schneider M. et al First experiences with an individual nasal olive in patients with hereditary haemorrhagic telangiectasia (HHT). European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery 2015; 272: 117-122
• 39 Werner JA, Lippert BM, Geisthoff UW. et al [Nd:YAG laser therapy of recurrent epistaxis in hereditary hemorrhagic telangiectasia]. Laryngorhinootologie 1997; 76: 495-501
• 40 Fiorella ML, Lillo L, Fiorella R. Diode laser in the treatment of epistaxis in patients with hereditary haemorrhagic telangiectasia. Acta Otorhinolaryngol Ital 2012; 32: 164-169
• 41 Luk L, Mace JC, Bhandarkar ND. et al Comparison of electrosurgical plasma coagulation and potassium-titanyl-phosphate laser photocoagulation for treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Int Forum Allergy Rhinol 2014; 4: 640-645
• 42 Bertlich M, Kashani F, Weiss BG. et al Safety and Efficacy of Blue Light Laser Treatment in Hereditary Hemorrhagic Telangiectasia. Lasers Surg Med 2020;
• 43 Folz BJ, Tennie J, Lippert BM. et al Natural history and control of epistaxis in a group of German patients with Rendu-Osler-Weber disease. Rhinology 2005; 43: 40-46
• 44 Folz BJ, Zoll B, Alfke H. et al Manifestations of hereditary hemorrhagic telangiectasia in children and adolescents. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery 2006; 263: 53-61
• 45 Aagaard KS, Kjeldsen AD, Torring PM. et al Comorbidity among HHT patients and their controls in a 20 years follow-up period. Orphanet J Rare Dis 2018; 13: 223
• 46 Shovlin CL, Millar CM, Droege F. et al Safety of direct oral anticoagulants in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2019; 14: 210
• 47 Vorselaars VM, Velthuis S, Swaans MJ. et al Percutaneous left atrial appendage closure-An alternative strategy for anticoagulation in atrial fibrillation and hereditary hemorrhagic telangiectasia?. Cardiovasc Diagn Ther 2015; 5: 49-53
• 48 Edwards CP, Shehata N, Faughnan ME. Hereditary hemorrhagic telangiectasia patients can tolerate anticoagulation. Annals of hematology 2012; 91: 1959-1968
• 49 Devlin HL, Hosman AE, Shovlin CL. Antiplatelet and anticoagulant agents in hereditary hemorrhagic telangiectasia. N Engl J Med 2013; 368: 876-878